2023. október 17., kedd 11:00 |
SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement (part 1) |
|
Zug, Switzerland, 17 October, 2023 (APA/OTS) - SHL Medical ("SHL"), a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical (Nasdaq: LFCR) ("Lifecore"), a fully integrated Contract Development and Manufacturing Organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. |
Through this partnership, Lifecore becomes a member of SHL's
recently announced Alliance Management program, an initiative
created to further strengthen SHL's vertically integrated business
model by facilitating customer engagement with other key players
within the drug delivery ecosystem.
SHL and Lifecore will, pursuant to the terms of its agreement,
exchange knowledge and experience in their respective fields,
enabling both companies to provide their customers unparalleled
guidance in CDMO services and best-in-class options for drug
delivery device development.
As the leader and pioneer of autoinjectors, SHL offers drug
delivery device solutions and vertically integrated capabilities for
the development, manufacturing, and final assembly of its
autoinjector products. The partnership with Lifecore will allow SHL
to recommend a trusted CDMO renowned for its proven proficiency and
robust quality systems in aseptic pharmaceutical manufacturing and
primary container filling, creating a comprehensive support system
across all stages of the autoinjector development and commercial
lifecycle.
"As a true partner to pharma and biotech, we believe in providing
full end-to-end solutions that enhance patients' quality of life and
enable patients' independence," said Kimberlee Steele, Managing
Director of SHL Pharma, SHL Medical's final assembly, labeling, and
packaging business unit in Florida. "We are excited to partner with
Lifecore to provide high-quality CDMO services matching SHL's own
high-touch approach to servicing our customers."
Darren Hieber, Senior Vice President of Corporate Development and
Partnerships for Lifecore commented, "We are continuously adapting
to keep pace with the evolution of healthcare treatments and
technologies and our deep expertise in the fill/finish of syringes
and vials is a perfect match for SHL's products. Our relationship
with SHL will expand the breadth of our offerings to our CDMO
customers, enabling them to deliver the benefits and convenience of
innovative drug delivery systems to their patients worldwide. We are
excited to be aligned with an industry leader, who has created a
business focused on patient-centric solutions through their unique,
convenient, high-quality product portfolio."
- Picture is available at AP
(https://apmultimedianewsroom.com/multimedia-newsroom/partners/news-aktuell)
- (continues)
|
|
|
|
|
|
|
2023. október 17., kedd 11:00 |
SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement (part 2) |
|
Zug, Switzerland, 17 October, 2023 (APA/OTS) - |
About SHL Medical
As a world-leading solutions provider of advanced drug delivery
systems, SHL Medical is the partner of choice for many leading
pharma and biotech companies. Driven by its company purpose -
Enabling Patients' Independence - SHL Medical offers patient-centric
solutions for the design, development, and manufacturing of
autoinjectors, pen injectors, as well as innovative specialty
delivery systems for large-volume and high-viscosity formulations.
It also offers final assembly, labeling, and packaging solutions for
its drug delivery systems.
In response to the rising trend in home therapy, SHL Medical has
increased its developmental work in the digital healthcare sector to
help improve the drug delivery ecosystem.
Located across Switzerland, Taiwan, Sweden, and the US, SHL
Medical's global team of experts collaborate seamlessly as one team
in utilizing its comprehensive in-house manufacturing capabilities.
The company's solutions offer customization and optimization for
each project while proactively weaving sustainability-driven
measures into its designs and processes to contribute to a cleaner
earth. For additional information, visit www.shl-medical.com.
About Lifecore Biomedical
Lifecore Biomedical, Inc. is a fully integrated contract
development and manufacturing organization (CDMO) that offers highly
differentiated capabilities in the development, fill and finish of
complex sterile injectable pharmaceutical products in syringes and
vials. As a leading manufacturer of premium, injectable grade
Hyaluronic Acid, Lifecore brings more than 40 years of expertise as
a partner for global and emerging biopharmaceutical and
biotechnology companies across multiple therapeutic categories to
bring their innovations to market. For more information about the
Company, visit Lifecore's website at www.lifecore.com.
Media contact Carl Gillblad Communications and Marketing Operations info@shl-medical.com +41 41 368 00 00
Alliance Management contact Alina Smotrova Corporate Development alliance@shl-medical.com +41 41 368 00 00
Lifecore Investor Relations Jeff Sonnek jeff.sonnek@icrinc.com (646) 277-1263
Important Cautions Regarding Forward-Looking Statements This press release contains forward-looking statements regarding
future events and future results, including the anticipated business
relationship between SHL and Lifecore, that are subject to the safe
harbor created under the Private Securities Litigation Reform Act of
1995 and other safe harbors under the Securities Act of 1933 and the
Securities Exchange Act of 1934. Words such as "anticipate",
"estimate", "expect", "project", "plan", "intend", "believe", "may",
"might", "will", "should", "can have", "likely" and similar
expressions are used to identify forward-looking statements. All
forward-looking statements involve certain risks and uncertainties
that could cause actual results to differ materially, including such
factors among others, the nature and requirements of the
relationship between SHL and Lifecore, the ability to achieve
acceptance of Lifecore's new products in the marketplace, and
government regulations affecting the companies' respective business.
For additional information about factors that could cause actual
results to differ materially from those described in the
forward-looking statements, please refer to Lifecore's filings with
the Securities and Exchange Commission, including the risk factors
contained in our most recent Quarterly Report on Form 10-Q and
Annual Report on Form 10-K/A. Forward-looking statements represent
management's current expectations and are inherently uncertain.
Except as required by law, neither company undertakes any obligation
to update forward-looking statements made to reflect subsequent
events or circumstances.
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
Forrás: OTS Üzleti Sajtószolgálat
MTI © Minden jog fenntartva.
|